Teva Branded Pharmaceutical Products R&d Llc

This study tested the long-term safety of a monthly injection called fremanezumab to prevent migraines in children aged 6 to 17. Over 500 participants received the shot for up to 84 months. Researchers tracked side effects, changes in migraine days, and overall safety to see if t…

This phase 1 trial tests a single injection of TV-44749, an extended-release form of olanzapine, in Chinese adults with stable schizophrenia. The study aims to check safety, tolerability, and how the drug moves through the body. Participants receive one of three doses of the inje…

This study tested a monthly injection of olanzapine (TV-44749) in 675 adults with schizophrenia to see if it controls symptoms better than a placebo. Participants received up to 14 injections over about a year. The goal is to offer a long-acting option that may improve treatment …

This completed Phase 1 trial tested three different slow-release versions of the schizophrenia drug olanzapine in 106 adults with schizophrenia or schizoaffective disorder. The goal was to see how the body absorbs and processes each version compared to the standard immediate-rele…

This study tested a new long-acting olanzapine injection (TV-44749) against the standard oral olanzapine pill in 153 people with schizophrenia. The goal was to see if the shot delivers similar drug levels and is safe. Participants received multiple doses over 21 weeks, with resea…

This study looked at how well and how safely deutetrabenazine works for Chinese adults with Huntington's disease who have chorea (uncontrolled movements). Fifty patients took the drug as part of their normal care. The main goal was to see if chorea scores improved, especially in …

This study tested different versions of the drug TEV-56286 (emrusolmin) in 47 healthy adults to see how well the body absorbs each form. Participants took a single dose of either a new formulation or a reference capsule, and researchers measured drug levels in the blood. The goal…